Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Hospital

Distinct Healthcare IPO Hong Kong: Private Provider Seeks $36M HKEX Listing

Fineline Cube Jan 29, 2026
Company Deals

Biogen’s Litifilimab Secures FDA Breakthrough Therapy Designation for Lupus

Fineline Cube Jan 29, 2026
Company Deals

Seamless Therapeutics Partners with Eli Lilly on $1.12B Hearing Loss Recombinase Deal

Fineline Cube Jan 29, 2026
Company Deals

Apeloa Partners with MindRank on AI Drug Development Platform

Fineline Cube Jan 28, 2026
Company Deals Medical Device

IVD Medical Launches Nipah Virus Detection Kit with AI Early Warning Platform

Fineline Cube Jan 28, 2026
Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Fineline Cube Jan 28, 2026
Company Drug

Changchun High‑Tech’s Firsekibart Filing Accepted for Non‑Infectious Uveitis

Fineline Cube Jan 29, 2026
Company Drug

Sino Biopharm’s TQA3605 Meets Endpoint in Hepatitis B Phase II Trial

Fineline Cube Jan 28, 2026
Company Deals

Novartis and Versant Ventures Launch Borealis Biosciences with a Focus on RNA Medicines for Kidney Diseases

Fineline Cube Aug 23, 2024

Novartis (NYSE: NVS), a Swiss pharmaceutical heavyweight, has joined forces with the US venture capital...

Company Drug

UK MHRA Approves Eisai and Biogen’s Alzheimer’s Drug Leqembi, Despite NICE Reimbursement Rejection

Fineline Cube Aug 23, 2024

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for Leqembi (lecanemab),...

Company

Ascentage Pharma’s 2024 Interim Results Highlight 477% YOY Revenue Growth and First-Ever Profitability

Fineline Cube Aug 23, 2024

Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced its 2024 interim...

Company

3SBio Inc. Reports 16% YOY Revenue Growth in 2024 Interim Financial Report, Highlighting Biomedicine Segment Strength

Fineline Cube Aug 23, 2024

3SBio Inc., a China-based biopharmaceutical company listed on the Hong Kong Stock Exchange (HKG: 1530),...

Company

Hangzhou Kang Ming’s ClouDr Posts Strong Financial Growth with Diversified Solutions and P2M Strategy

Fineline Cube Aug 23, 2024

Hangzhou Kang Ming Information Technology Co., Ltd, trading under the moniker “ClouDr” on the Hong...

Company Drug

Everest Medicines Launches Trial for Personalized mRNA Cancer Vaccine EVM16 in Solid Tumors

Fineline Cube Aug 23, 2024

Everest Medicines, a biopharmaceutical company based in China and listed on the Hong Kong Stock...

Company Drug

Regeneron’s Linvoseltamab Faces FDA Complete Response Letter, Awaiting Reinspection of Manufacturer

Fineline Cube Aug 23, 2024

Regeneron Pharmaceuticals Inc., a leading biopharmaceutical company based in the US and listed on the...

Company Legal / IP

Astellas Pharma Employee in China Formally Indicted on Espionage Suspicion

Fineline Cube Aug 23, 2024

Astellas Pharma Inc., a Japanese pharmaceutical company listed on the Tokyo Stock Exchange (TYO: 4503),...

Company Drug

CK Life Sciences’ Halneuron Receives FDA Fast-Track Designation for Chemotherapy-Induced Neuropathic Pain

Fineline Cube Aug 23, 2024

CK Life Sciences (HKG: 0775), a biopharmaceutical company headquartered in China, has received fast-track designation...

Company Deals

GSC to Distribute Hecin’s Innovative PCR and RT-PCR Solutions in Middle Eastern Markets

Fineline Cube Aug 23, 2024

Gulf Scientific Corporation (GSC), a prominent life sciences service provider headquartered in Dubai, United Arab...

Company

WuXi Biologics Reports Flat Revenues with Growth in Non-COVID-19 Projects in 2024H1 Financial Report

Fineline Cube Aug 23, 2024

WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) from China,...

Company Drug

Innovent Biologics’ Fulzerasib Receives NMPA Approval for Advanced NSCLC Treatment in China

Fineline Cube Aug 23, 2024

Innovent Biologics Inc., a biopharmaceutical company based in China and listed on the Hong Kong...

Policy / Regulatory

China’s NHC and NHSA Intensify Efforts to Stabilize Drug Supply and Prices Amid Shortages

Fineline Cube Aug 22, 2024

The National Health Commission (NHC) has published a report titled “Recent Work on Securing Supply...

Policy / Regulatory

China Commits to Optimizing Market Access for Emerging Sectors and Global Scientific Collaboration

Fineline Cube Aug 22, 2024

The General Office of the Communist Party of China (CPC) Central Committee and the State...

Company Drug

Qilu Pharmaceutical’s Biosimilar Ranibizumab Receives NMPA Approval, Marking a First in China

Fineline Cube Aug 22, 2024

Qilu Pharmaceutical, a Chinese pharmaceutical company, has announced that its biosimilar version of Novartis’s blockbuster...

Company Drug

BrightGene Bio Receives FDA Clearance for Generic Eribulin APIs, Advancing in Breast Cancer Treatment

Fineline Cube Aug 22, 2024

BrightGene Bio-Medical Technology Co., Ltd, a Chinese pharmaceutical company listed on the Shanghai Stock Exchange...

Company

Sisram Medical Reports 2024 Interim Revenues with Growth in Key Regions and New Product Launches

Fineline Cube Aug 22, 2024

Sisram Medical Ltd (HKG: 1696), an Israel-based subsidiary of the Fosun Pharmaceutical Group, has released...

Company Drug

Daiichi Sankyo Launches Tarlige for Diabetes Peripheral Neuropathic Pain in China

Fineline Cube Aug 22, 2024

Daiichi Sankyo (TYO: 4568), a leading Japanese pharmaceutical company, has announced the official market launch...

Company Deals

Changchun GeneScience Pharmaceutical Expands Reach with HuChuang Union Partnership

Fineline Cube Aug 22, 2024

Changchun GeneScience Pharmaceutical Co., Ltd, a Chinese pharmaceutical enterprise, has established a partnership with HuChuang...

Company Deals

SynthAsia and Shanghai General Hospital Partner to Advance Diabetic Retinopathy Research

Fineline Cube Aug 22, 2024

SynthAsia has forged a strategic partnership with Shanghai General Hospital, focusing on scientific innovation within...

Posts pagination

1 … 259 260 261 … 615

Recent updates

  • Servier Oncology Revenue Drives 16% Growth, US Sales Surge 70%
  • Changchun High‑Tech’s Firsekibart Filing Accepted for Non‑Infectious Uveitis
  • Danaher Q4 Revenue Grows 3% to $24.6B on Biotech and Diagnostics Innovation
  • Distinct Healthcare IPO Hong Kong: Private Provider Seeks $36M HKEX Listing
  • Merck Establishes Chongqing China Branch in Milestone Expansion
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Servier Oncology Revenue Drives 16% Growth, US Sales Surge 70%

Company Drug

Changchun High‑Tech’s Firsekibart Filing Accepted for Non‑Infectious Uveitis

Company

Danaher Q4 Revenue Grows 3% to $24.6B on Biotech and Diagnostics Innovation

Company Deals Hospital

Distinct Healthcare IPO Hong Kong: Private Provider Seeks $36M HKEX Listing

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.